{"preliminary_commentary":{"by_channel":{"youtube":3,"podcast":3,"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00940602\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["deferasirox"]],"indication":"transfusion-dependent low- to intermediate-1-risk myelodysplastic syndromes","name":"TELESTO","nct_id":"NCT00940602","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=telesto-nct00940602. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TELESTO","arms":[{"description":"10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.","label":"Deferasirox","type":"EXPERIMENTAL"},{"description":"10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2018-02-27","type":"ACTUAL"},"conditions":["Myelodysplastic Syndromes"],"enrollment":{"count":225,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Deferasirox","otherNames":["ICL670, Exjade®"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2020-11-23","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2018-02-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-free Survival","timeFrame":"Day 1 to end of treatment period, approx. 7 years"}],"references":[{"citation":"Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G; TELESTO Study Investigators. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Ann Intern Med. 2020 Apr 21;172(8):513-522. doi: 10.7326/M19-0916. Epub 2020 Mar 24.","pmid":"32203980","type":"DERIVED"}],"start_date":{"date":"2010-03-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study","url":"https://clinicaltrials.gov/study/NCT00940602"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/telesto-nct00940602"}